Cancer Anorexia-Cachexia Syndrome – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Cancer Anorexia-Cachexia Syndrome – Pipeline Review, H2 2019’, provides an overview of the Cancer Anorexia-Cachexia Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome

– The report reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cancer Anorexia-Cachexia Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Cancer Anorexia-Cachexia Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AAVogen Inc

Abreos Biosciences Inc

Actimed Therapeutics Ltd

Aeterna Zentaris Inc

Aphios Corp

Artelo Biosciences Inc

AVEO Oncology Inc

Betula Pharma

Energenesis Biomedical Co Ltd

Extend Biosciences Inc

Fountain Biopharma Inc

Helsinn Group

NGM Biopharmaceuticals Inc

Paradigm Biopharmaceuticals Ltd

RaQualia Pharma Inc

Signablok Inc

Spinalcyte Llc

StemMed Ltd

TCI Peptide Therapeutics

Teijin Pharma Ltd

Vascular BioSciences

XBiotech Inc

Zeria Pharmaceutical Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Cancer Anorexia-Cachexia Syndrome - Overview 5

Cancer Anorexia-Cachexia Syndrome - Therapeutics Development 6

Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment 13

Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development 21

Cancer Anorexia-Cachexia Syndrome - Drug Profiles 28

Cancer Anorexia-Cachexia Syndrome - Dormant Projects 94

Cancer Anorexia-Cachexia Syndrome - Discontinued Products 96

Cancer Anorexia-Cachexia Syndrome - Product Development Milestones 97

Appendix 108

List of Tables

“List of Tables

Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by AAVogen Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Abreos Biosciences Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Actimed Therapeutics Ltd, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Aeterna Zentaris Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Aphios Corp, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Artelo Biosciences Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by AVEO Oncology Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Betula Pharma, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Energenesis Biomedical Co Ltd, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Extend Biosciences Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Fountain Biopharma Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Helsinn Group, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by NGM Biopharmaceuticals Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by RaQualia Pharma Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Signablok Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Spinalcyte Llc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by StemMed Ltd, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by TCI Peptide Therapeutics, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Teijin Pharma Ltd, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Vascular BioSciences, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by XBiotech Inc, H2 2019

Cancer Anorexia-Cachexia Syndrome – Pipeline by Zeria Pharmaceutical Co Ltd, H2 2019

Cancer Anorexia-Cachexia Syndrome – Dormant Projects, H2 2019

Cancer Anorexia-Cachexia Syndrome – Dormant Projects, H2 2019 (Contd..1), H2 2019

Cancer Anorexia-Cachexia Syndrome – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports